Blood Cancer Journal - Table of Contents alert Volume 1 November 2011

TABLE OF CONTENTS Volume 1, November 2011 In this issue Original Articles Letter to the Editor Sign up for e-alerts Web feed Advertisement Did you know these highly cited articles were published in Blood Cancer Journal? See what your colleagues have been reading: Research recommendations toward a better understanding of the causes of childhood leukemia Myeloma cells suppress osteoblasts through sclerostin secretion Functional assessment of p53 in chronic lymphocytic leukemia   Original Articles Top Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia S Hart, K C Goh, V Novotny-Diermayr, Y C Tan, B Madan, C Amalini, L C Ong, B Kheng, A Cheong, J Zhou, W J Chng and J M Wood Blood Cancer J 2011 1: e44; 10.1038/bcj.2011.43 Abstract | Full Text FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia Z Pašaliç, P A Greif, V Jurinoviç, M Mulaw, P M Kakadia, B Tizazu, L Fröhlich-Archangelo, A Krause and S K Bohlander Blood Cancer J 2011 1: e42; 10.1038/bcj.2011.40 Abstract | Full Text Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms K L Rice, X Lin, K Wolniak, B L Ebert, W Berkofsky-Fessler, M Buzzai, Y Sun, C Xi, P Elkin, R Levine, T Golub, D G Gilliland, J D Crispino, J D Licht and W Zhang Blood Cancer J 2011 1: e40; 10.1038/bcj.2011.39 Abstract | Full Text Letter to the Editor Top Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells M M da Rocha, L Otero, T F Padilha, J Dobbin, C de Souza Fernandez, E Abdelhay and T de Souza Fernandez Blood Cancer J 2011 1: e45; 10.1038/bcj.2011.45 Full Text Advertisement A personal note - 40 years after the signing of the Cancer Act FREE Nat. Rev. Clin. Oncol ¦ doi:10.1038/nrclinonc.2011.168 The Cancer Act that was signed by President Nixon 40 years ago had a mandate “to support research and the application of the results of research, to reduce the incidence, morbidity and mortality from cancer.” It has succeeded in many of these aims by focusing on basic research, as this personal account from a former Director of the National Cancer Institute testifies.   You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.